Location: San Francisco, California, United States
Job Category: Research and Early Development
Work Location: 1500 Owens Street 94158
Organization: Translational Medicine
Employee Status: Full-time
Job Type: Regular
The position will require an individual with exceptional scientific insight and excellent communication and collaboration skills. Applications are encouraged from those looking to bridge the capabilities and strengths of academic and industrial research environments to enable the development of truly innovative, life-changing therapies. As a member of an integrated discovery research and early development team, this role will also involve collaboration with discovery biology and chemistry researchers, clinicians, and computational biologists. A keen interest in the emerging biology and therapeutic potential of regulated protein turnover and stability will be helpful. This position will report to a translational leader within the Protein Homeostasis Thematic center of Excellence, and will be located in San Francisco, California.
- Key contributor to translational science in the context of early-phase clinical trials
- Collaborate with discovery biologists, computational biologists, and clinicians to translate understanding of in vitro and in vivo drug mechanisms and disease biology into efficient clinical trials
- Define testable hypotheses and recommendations on dose and schedule, combinations, and subsets to optimize efficacy and patient outcomes
- Design experiments to test hypotheses from clinical observations in preclinical model systems
- Author and oversee writing of study reports, patents, assay protocols, and peer-reviewed publications. Presentation of methods, results and conclusions to publishable standards
- Work across geographies and scientific domains
- Analyze clinical and preclinical data to increase understanding of in vivo exposures, associated pathway modulations in different tissues and cells, and consequences for both efficacy and toxicity
- Evaluate and advise on clinical trial biomarker/exploratory endpoint strategies, collect and analyze patient data to inform clinical development
- Define data that will increase understanding of drug action and strategies to acquire it
- Interact with project teams, academic collaborators and contract laboratories to design in vitro and in vivo studies to evaluate drug candidates
- Manage relationships and critically review data from contract labs and academic collaborators
- Present work at group meetings, internal forums and scientific conferences
- Ph.D. in Cell Biology, Molecular Biology, Biochemistry or a related scientific discipline with at least 4 years of pharmaceutical industry experience.
- Strong base of cancer biology and drug development knowledge and experience
- Real-world clinical trial translational experience and understanding of key challenges and decisions in clinical development
- Expert in cell based assays and pharmacology models used to interrogate MOA of cancer drugs (mammalian cancer cell phenotype and signaling assays, gene expression manipulations and analysis, immune function and cytokine analysis, cancer efficacy models)
- Ability to interpret and summarize scientific data in an accurate, critical and concise manner
- Flexible and adaptable to changing priorities
- Experienced in the integration of preclinical research through to clinical drug development
- Highly effective teamwork and interpersonal skills
- Exceptional written and verbal communications skills
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
"At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients."
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.